Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Wynn Resorts, Limited — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Wynn Resorts, Limited trades at $99.4 (market cap $10.35B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.9× Wynn Resorts, Limited's market cap, and Wynn Resorts, Limited pays a 1% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WYNN | |
|---|---|---|
Market Cap | $39.89B | $10.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $133.34 |
52-Week Low | $278.09 | $94.78 |
Enterprise Value | $38.15B | $20.72B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Wynn Resorts (WYNN) trades at $99.77, up 0.95% on the day, but remains 13.4% down year-to-date amid bearish technical signals. The company reported Q1 2026 EPS of $1.25, meeting expectations, but has missed estimates in three of the last four quarters. Revenue growth continues with $7.14B in 2025, though net margins have compressed from 11.17% in 2023 to 4.58% in 2025. High debt levels persist with $10.50B long-term debt, while analyst consensus remains strongly bullish with a $134.60 price target.
The outlook is mixed: strong analyst support and luxury market positioning offer upside potential, but margin pressure, high leverage, and recent earnings misses present significant risks. The stock's current valuation at 28.59 P/E appears stretched given declining profitability, making execution on future growth critical for investor returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
